Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.
Pei-Wei ShuengChun-Chieh HuangYu-Ming LiuYuan-Hong WuPin-I HuangSang-Hue YenKuan-Heng LinChen-Xiong HsuPublished in: Thoracic cancer (2022)
Our results suggest that NCRT+S can provide a favorable survival for patients with ESCC, especially in patients who achieved pCR. The optimal radiation dose might be 55-60 Gy for patients receiving DCCRT via modern radiation techniques. Further randomized clinical studies are required to confirm the survival benefits between NCRT+S and DCCRT with escalated dose.